Unilab ramps up production of meds amid high demand; denies hiking prices

enablePagination: false
maxItemsPerPage: 10
maxPaginationLinks: 10


Metro Manila (CNN Philippines, January 15)— Local pharmaceutical company Unilab refuted claims it was withholding stocks and hiking prices of flu, fever, and other medicines amid an increase in demand.

"We refer to rumors circulating that Unilab is withholding stocks and increasing the prices of Biogesic, Bioflu, Neozep, Solmux, and Decolgen, which allegedly caused the out of stock situation in drugstores. The rumor is not true. Unilab has not increased the prices of these brands," it said in an advisory on Friday.

Unilab also disclosed it has ramped up the production of medicines for fever, coughs, and colds to cater to customers' needs.

"We continue to manufacture, and have in fact, increased the manufacturing volume of these products to serve the extraordinary demand," the company said.

Reports of long lines in pharmacies surfaced earlier this month, with some netizens also citing difficulties in buying paracetamols and other drugs.

At the time, Unilab admitted that some branded paracetamols were off the market due to the surge in demand amid the steady rise in COVID-19 cases in the country. The company said it was working to speed up the replenishment of the products.

RELATED: Some branded paracetamol out of stock; govt urges use of generic drugs

Meanwhile, the government has set a purchase cap for over-the-counter fever and flu medicines to prevent possible hoarding.